Together with different types of drugs, medicinal herbs and cosmetics may be involved in liver damage.2 Postinfantile giant cell hepatitis (PGCH) is a rare entity secondary to a nonspecific reaction to toxins, drugs, or viruses, although no causative agent has been found in many cases.3, 4 Importantly, several patients have exhibited autoimmune characteristics and have responded to immunosuppressive therapy.5, 6 The clinical spectrum of PGCH is variable; according to some authors,3, 7 the disease in its natural course is usually fulminant and within months progresses to cirrhosis, which will lead to death or a requirement for liver transplantation. However, a benign course in these patients can also be observed.

Here we discuss a 38-year-old woman who, having PGCH and features of AIH

associated with a drug used to prevent hair loss, responded to corticosteroids plus azathioprine. The patient, presenting Kinase Inhibitor Library mouse progressive jaundice (total bilirubin level = 28.7 mg/dL) without pain during the previous 3 weeks, was admitted to our hospital. The laboratory investigation revealed elevated serum levels of aspartate aminotransferase (714 IU/L), alanine aminotransferase (465 IU/L), gamma-glutamyltransferase (98 IU/L), and alkaline phosphatase (268 IU/L), and she was positive for antinuclear antibody (titer = 1/160) with normal immunoglobulins. The only relevant previous history was her treatment for more than 10 months with Pil-Food (Laboratorio Serra Pamies, Reus, Spain) to prevent hair loss. An ultrasonography CP-690550 price examination found only regular hepatomegaly, and percutaneous liver biopsy was performed. A histological study (Fig. 1) showed not only a conserved architectural structure but also extensive areas of multinucleate giant cells, portal tract enlargement with bridging necrosis, intense inflammation of the parenchyma, and liver cell necrosis with regenerative changes and hyperplasia of the mononuclear phagocytic system. Furthermore, marked intracanalicular and hepatocellular cholestasis was observed. When she was admitted to the hospital, the Pil-Food therapy was stopped,

and treatment with ursodeoxycholic acid (14 mg/kg/day) was initiated; substantial analytical changes were not attained. Because of the probable AIH component, a course of methylprednisolone Tau-protein kinase (60 mg/day) was started, and the dose was subsequently tapered until total remission was achieved. As a unique maintenance therapy, azathioprine (50 mg/day initially and 25 mg/day after the first year) was used. In month 12 after the diagnosis and treatment, the biochemical investigation was completely normal (aspartate aminotransferase level = 14 IU/L, alanine aminotransferase level = 12 IU/L, total bilirubin level = 0.5 mg/dL, alkaline phosphatase level = 62 IU/L, and gamma-glutamyltransferase level = 12 IU/L); her antinuclear antibody positivity persisted (titer = 1/80).